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To family, friends and home 
Nevertheless, I long -  I pine, all my days –  
to travel home and see the dawn of my return.  
And if a god will wreck me yet again on the wine-dark sea,  
I can bear that too, with a spirit tempered to endure.   
Much have I suffered, labored long and hard by now 
in the waves and wars. Add this to the total –  
bring the trial on! 
- Homer, the Odyssey

ABSTRACT 
Acute ischemic stroke (AIS) is caused by the sudden occlusion of a major artery 
of the brain, and results in infarction and severe ischemia within affected brain 
regions. If ischemic regions are rapidly revascularized, the neurological disabil-
ity resulting from AIS can be significantly reduced. Accordingly, endovascular 
thrombectomy aims to restore blood flow to ischemic tissue-at-risk, penumbra, 
that remains viable in the short-term by virtue of collateral blood flow and an 
increased extraction of oxygen (OEF) from the blood. 
Diagnostic imaging is an essential component in the identification of patients who 
are suitable for revasculatory treatment. The aim of this thesis was to investigate 
AIS pathophysiology, with a special focus on oxygen metabolism and neuroinflam-
mation, and subsequently to develop and improve methods for the identification 
of penumbra tissue through imaging with magnetic resonance imaging (MRI) and 
positron emission tomography (PET). To achieve this, we used a middle cerebral 
artery M2-segment occlusion model in rat that had previously been designed to 
increase the translational potential of experimental AIS research (M2CAO). 
In paper I we employed the PET tracer [11C]PBR28 to longitudinally profile the 
neuroinflammatory response during the first 14 days following transient M2CAO. 
We complemented PET examinations with ex-vivo immunohistochemistry (IHC). 
Results validated [11C]PBR28 and revealed early microglial activation and glial 
scar formation following M2CAO. In paper II, we used diffusion- and perfusion 
weighted MRI (DWI, PWI) to outline the emergence and expansion of ischemic 
injury at the expense of the penumbra during AIS. We used the established DWI/
PWI mismatch concept as a surrogate of the penumbra. Results showed that although 
the initial spread of ischemic injury is rapid, not all tissue contained in the DWI/
PWI mismatch is at risk of infarction. In paper III, we assembled a blood oxygen 
level dependent MRI protocol which was combined with PWI. The protocol was 
used to approximate regional tissue OEF during M2CAO and after blood flow had 
been restored. When combined with DWI, oxygen metabolism MRI achieved an 
improved penumbra specificity when compared to the DWI/PWI mismatch pro-
tocol used in paper II. In paper IV, we compared PET tracers [18F]FMISO and 
[64Cu]CuATSM in identifying tissue hypoxia resulting from M2CAO, and inves-
tigated the effects of hypoxia on ischemic tissue using IHC analysis. [18F]FMISO 
was superior to [64Cu]CuATSM in identifying tissue hypoxia. In conclusion, the 
imaging methodologies investigated in this study have high diagnostic potential 
in AIS as well as in cases of chronic cerebral hypoperfusion. 
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11. BACKGROUND   
Acute ischemic stroke (AIS) is a leading cause of death and neurological disability 
worldwide(1). A sudden occlusion of a large brain vessel will result in the rapid 
infarction of affected tissue within the so-called ischemic core. In the following 
hours, irreversible damage will appear in the surrounding tissue-at-risk, referred to 
as ischemic penumbra, unless blood flow is restored(2). The acute revascularisa-
tion of salvageable tissue-at-risk accordingly remains the long-standing therapeutic 
target in AIS, with neuroimaging serving as the foremost diagnostic instrument(3, 
4). The therapeutic aim is to stem the spread of infarction within the ischemic 
penumbra, which are regions that have not yet suffered irreversible damage, and 
where an increased oxygen extraction fraction (OEF) from blood to brain tissue 
sustains tissue viability in the short-term(5). The aim of diagnostic imaging is to 
achieve examinations with a high sensitivity and specificity for penumbra, but that 
are still practical enough to be clinically applicable. In 2015, a series randomized 
trials showed the benefits of endovascular mechanical thrombectomy in the first 
hours after stroke, when aided by diagnostic imaging(6). Since then, other studies 
have produced evidence of prolonged penumbra viability in a proportion of AIS 
cases(7, 8), thereby increasing the demand on imaging techniques to achieve high 
penumbra specificity in order to enable clinicians to proceed with revasculatory 
interventions also in these patients. There is also an increasing interest in improv-
ing diagnostic imaging of patients presenting with symptoms potentially caused 
by subacute to chronic cerebral hypoperfusion (CCH)(9), a condition associated 
with neurodegenerative disorders and dementia. While AIS is caused by a sudden 
and dramatic loss tissue perfusion, the less severe but unremitting condition of 
CCH likewise results in an inadequate supply of glucose and oxygen to affected 
brain regions. As in AIS, this impedes normal neurological function and may result 
in a regional increase in OEF in order to sustain cellular viability. The causes of 
CCH include CBF-limiting pathologies of the cerebral vasculature which may be 
alleviated through mechanical thrombectomy. However, as in AIS, this requires 
diagnostic imaging capable of assisting the clinician with the information needed 
to assess whether to proceed with the revasculatory treatment. Neuroimaging is 
now capable of providing a large amount of different examinations, all with varying 
value for the process of diagnostic decision-making. Information on tissue status, 
perfusion, site of occlusion and collateral flow status(10) are routinely available 
using computerized tomography (CT) and magnetic resonance imaging (MRI). 
Blood oxygen level dependent (BOLD) techniques for MRI, and positron emission 
tomography (PET) tracers capable of identifying inflammation and hypoxia have the 
potential to improve the future of AIS- as well as CCH associated health care(11). 
21.1 The ischemic penumbra    
1.1.1 Time is brain 
In 1981, Astrup and colleagues described the ischemic penumbra as functionally 
silent yet structurally intact brain tissue, lingering between the blood flow thresh-
olds of electrical inactivity and irreversible damage(12). In AIS-associated health 
care, the expression “time is brain” (Figure 1) is used to emphasize the importance 
of rapid intervention and early restoration of blood flow (reperfusion) in order to 
salvage the penumbra(13). We now understand that the penumbra is kept viable 
in the short-term by metabolic adjustments(14) such as increased OEF, as well as 
by the recruitment of collateral vessels(15) which provide compensatory blood 
flow from unaffected arteries in the brain. 
Figure 1. Time is brain. In acute ischemic stroke, there is a continuous expansion of the 
irreversibly damaged ischemic core (blue). The tissue-at-risk, known as penumbra (green), 
will thereby succumb to infarction unless blood flow is restored in time. 
1.1.2 Misery perfusion 
Demands on the circulatory system to maintain a constant delivery of oxygenated 
blood to the brain are high, leaving neuronal tissue susceptible to injury and func-
tional impairment in the case of a sudden drop in tissue perfusion. The healthy brain 
implements hemodynamic autoregulation in order to compensate for fluctuations 
in the mean arterial blood pressure. The autoregulatory mechanism is maintained 
by the continual dilation and constriction of the vascular bed, which allows cer-
ebral regions to sustain a constant ratio between cerebral blood flow (CBF) and 
the metabolic requirements for oxygen and glucose(16). 
3Misery perfusion(17) is a term used to describe the pathophysiological state dur-
ing which metabolic and hemodynamic changes are employed to compensate for 
an acute loss in cerebral perfusion pressure (CPP), as in the case of AIS or CCH. 
The initial reaction following a sudden loss of CPP is a rapid dilation of the vas-
cular bed within affected regions, as well as of the leptomeningeal anastomoses 
(LMAs) that connect the distal cortical branches of the major arteries of the brain 
(18-20). The dilation of small arteries and arterioles increases the local cerebral 
blood volume (CBV) within affected areas, thereby raising the CBV/CBF ratio. 
This is equivalent to a decrease in the rate of large-vessel cerebral circulation and 
a corresponding increase in the mean transit time (MTT) of red blood cells through 
tissue (16). A substantial decrease in CBF and an increase in MTT will result in 
inadequate amounts of oxygen being supplied to the brain tissue, a pathological 
condition known as ischemia. 
1.1.3 Increased OEF sustains the penumbra
The energy requirements of the human brain are sustained almost entirely by the 
oxidative metabolism of glucose. In total, approximately three quarters of the 
adenosine triphosphate (ATP) produced in neuronal tissue is expended to power 
processes necessary for neuronal function, with the remaining quarter allocated to 
cellular housekeeping(21). If CPP decreases beyond the vasodilatory capacity of 
the cerebral autoregulation this will result in ischemia. The resulting tissue damage 
is a product of both the severity and the duration of the perfusion deficit. A severe 
reduction to CBF levels of 12 – 22 ml/ 100 g/ min will cause ischemic damage if 
left unresolved, but may in the short term be compensated by metabolic adjust-
ment. In order to sustain the cerebral metabolic rate of oxygen (CMRO2) necessary 
for cell survival, the OEF of affected tissue regions becomes increased. Imaging 
modalities like PET and MRI have the potential to identify the ischemic penumbra 
by examining the oxygen metabolism of ischemic tissue. More specifically, a  
40% increase OEF in conjunction with a sustained CMRO2 has been proposed as 
a specific marker of the ischemic penumbra, and has been employed in imaging 
regimes designed with the aim of being able to identify tissue-at-risk (5, 14, 22). 
1.2 Imaging modalities – Overview  
1.2.1 Magnetic Resonance Imaging 
MRI(21, 22) is an imaging modality routinely employed in research as well as in 
clinical practice. Like CT, MRI produces greyscale cross sectional images with 
high resolution. Unlike CT, PET and conventional X-ray, MRI does not produce 
ionizing radiation but instead use powerful magnetic fields to achieve high contrast 
images of soft tissue, fat and fluids. 
4MRI utilizes the abundance of hydrogen protons contained in the bodies of humans 
and animals. These protons have spin, which may be described as a continuous 
rotation around their own axes which produces localized magnetic moments. In 
their natural state, the magnetic moments within an object, such as the human 
body, are randomly arranged in a manner that maintains magnetic equilibrium. 
Magnetic moments maintain a processing motion around the any magnetic field 
that acts upon them. Precession occurs at a frequency (the Larmor frequency) 
which is defined by the gyromagnetic ratio and is proportional to the strength of 
the magnetic field. If subjected to the strong magnetic field (B0) of a MRI scan-
ner the direction of magnetic moments will become distributed in such a way that 
produces a net magnetization vector either parallel or anti-parallel to the direction 
of B0. MRI utilizes the net magnetization vector by applying to it radiofrequency 
(RF) pulses precisely matching the Larmor frequency. When subjected to such 
RF pulses, protons will absorb energy and move to a higher state of energy, a pro-
cess referred to as excitation. Excitation will push the net magnetization vector 
to leave the equilibrium and move, flip, into an angle (commonly 0-90 degrees) 
relative to B0. In addition to flipping, the magnetic moments will begin to precess 
in a synchronized manner, achieving phase-coherence. 
In order to enable MRI to specify the position of protons within the examined 
object, additional magnetic fields in the form of gradients are applied. The magnetic 
gradient will modify B0 strength, thereby increasing the Larmor frequency of exam-
ined protons along the direction of the gradient. By tailoring the frequency of the 
RF pulse used for excitation to match the Larmor frequency, proton spins achieve 
precession coherence in one slice at the time, and the position of the examined 
protons along the gradient can be determined in in a process called slice-selection. 
Subsequently, more gradients are applied in perpendicular directions to the slice-
select gradient. These gradients will affect the Larmor frequency, as well as the 
phase of the net magnetization precession. The net magnetization precession will 
induce a voltage in the receiver coil of the MRI. The voltage arising from indi-
vidual voxels will be modulated accordingly to the effects on net magnetization 
precession by the applied gradients. The marginal changes to voltage produced 
by gradients can then be used to locate individual voxels in space. 
Relaxation 
Once the RF pulse used for excitation is discontinued, protons that have achieved 
a higher state of energy, including precession coherence, will inevitably return to 
a lower energy equilibrium. This process is referred to as relaxation and is made 
up by two distinct components; longitudinal and transverse relaxation which are 
used in T1- and T2- weighted imaging, respectively (T1WI, T2WI). 
5T1WI is used mainly to attain high contrast, anatomical images of soft tissue. 
During longitudinal process of T1-relaxation, the excess energy of the proton 
is dispersed into the surrounding molecular environment in which the proton is 
located. Large molecules, such as fat, will reestablish its net magnetization vec-
tor more rapidly than tissues made up by more mobile molecules, such as water. 
Accordingly, the longitudinal relaxation is faster in fat than in water, giving rise 
to a high signal in T1WI. 
T2WI is routinely used to identify soft tissue pathology. T2WI is based on the 
process referred to as transverse relaxation. As with the longitudinal relaxation 
harnessed in T1WI, transverse relaxation is dependent on the size and properties 
of the molecules that make up the examined tissue. However, transverse relaxa-
tion is a different and independent process to longitudinal relaxation. As described 
above, the RF pulse used to move the net magnetization vector into a direction 
perpendicular to B0 also results in precession phase coherence. Precession con-
stitutes a transverse component of the net magnetization vector. The transverse 
magnetization vector will decay as its precession begins lose phase coherence. 
This occurs because protons become affected by microscopic inhomogeneities 
within the magnetic field. 
1.2.2 Positron Emission Tomography 
PET(25, 26) is an imaging modality capable of tracking disease-associated pro-
cesses such as metabolism, hypoxia, inflammation as well as the distribution and 
kinetics of pharmaceuticals. PET employs radiotracers, which consist of probe 
molecules that have been attached to positron emitting radionuclides. Positrons 
are positively charged particles of comparable mass to electrons. A radionuclide 
is unstable form of a common element which emits radioactivity as it releases 
excess energy, a process referred to as decay. Commonly used radionuclides are 
11C (half-life: 20.3 min), 13N (9.97 min), 15O (124 s) and 18F (110 min). The most 
used radiotracer by far is Fluorodeoxyglucose ([18F]FDG), radioactive sugar, which 
is employed to examine tissue metabolism in several pathological condiitons. 
Once injected into the circulation of a human or animal, the radiotracer will exhibit 
an affinity for specific sites onto which they undergo reversible or irreversible 
binding. The radionuclide component of the tracer undergoes a continuous decay 
during which positrons are emitted at high velocity. As the positron travels through 
tissue it interacts with and ionizes the biological material, resulting in a gradual 
decrease in velocity. Ultimately there occurs an interaction with an electron, com-
monly a short distance from the site of emission. The positron-electron interaction 
results in both particles being annihilated. The reaction produces two high energy 
photons (511 keV) which are immediately projected in opposite directions. These 
6photons are registered as pulses by a 360° detector ring surrounding the examined 
subject. Subsequently, coincidence analysis is performed based on the assump-
tion that specific photons will have reached opposing detector elements within a 
timeframe of a few nanoseconds. By disregarding photons pulses which were not 
matched at the opposing element within this time frame, the approximate location 
of radioactive decay can be established. 
1.3 Imaging irreversibly damaged tissue with MRI 
The ischemic penumbra consists of ischemic but viable tissue that may be salvaged 
through revasculatory treatment such as pharmacological thrombolysis or mechani-
cal thrombectomy.  It is, however, due to the risk of unwarranted hemorrhagic or 
other complications, not appropriate to perform a revasculatory intervention on 
every AIS patient or in every patient where CCH is suspected.  The presence of 
extensive tissue damage and a low likelihood of remaining penumbra is contra 
indicative to revasculatory intervention. Identifying irreversible tissue damage 
in relation to salvageable tissue through imaging is thereby an important aim in 
the diagnostic process. This is especially relevant in cases of so-called malignant 
infarction(27), where collateral blood flow is hindered by a proximal occlusion in 
combination with insufficient LMA collaterals. The loss of collateral blood flow 
will result in fast progression of ischemic injury at the expense of penumbra tis-
sue. In such cases, the potential gain of interventional treatment is outweighed by 
the high risk of serious adverse events such as hemorrhage. In routine imaging, 
the two MRI techniques used to identify irreversibly damaged tissue are DWI and 
T2WI. The vasogenic edema that causes T2 – signal increase is likely caused by 
blood-brain-barrier breakdown that arises from progressive vasogenic edema. (5, 
28, 29). T2WI is capable of identifying ischemic injury in the brain, however, it 
is not adequately sensitive to perform this task in the hyperacute phase of AIS. 
1.3.1 Diffusion weighted imaging 
On a cellular level, unless blood flow is restored, energy-dependent ion-transport-
ers will fail, causing cytotoxic edema which results in the gradual swelling and 
ultimately destruction of affected tissues. On a macroscopic level these processes 
entail a significant reduction of the extra-cellular space which decreases the free 
diffusion of water molecules. 
The application of diffusion weighted imaging (DWI) for the detection of ischemic 
injury in the brain was introduced in 1990. It first described the rapid and dramatic 
decline of the apparent diffusion coefficient (ADC) of affected brain regions in 
cats subject to MCA occlusion(30) (for DWI review see(31)). Significantly, these 
changes were detectable before any T2-signal increase. (5, 28, 29). To date, DWI 
7has proven more effective than any other imaging technique, including routinely 
used CT, for the early detection of ischemia-induced brain damage(32). 
The methodology of DWI utilizes a pair of opposing diffusion gradient pulses 
superimposed on a T2-weighted spin-echo pulse sequence.  In short, an initial 
diffusion gradient pulse will assign a spatially specific phase shift to the protons 
of water molecules contained within an examined area. The subsequent diffusion 
gradient pulse inverses the previously applied phase-shift, resulting in the complete 
restoration of phase for stationary protons while moving protons acquire phase 
dispersal, and thereby signal loss, in proportion to their degree of diffusion.  Since 
DWI is superimposed on a T2-image, it is affected also by the factors contributing 
to T2-signal, a MRI phenomenon referred to as “T2-shine through”. As mentioned 
previously, T2WI is sensitive to the vasogenic edema that results from ischemic 
blood brain barrier breakdown. To counteract these confounders, tissue ADC is 
calculated. In contrast to DWI, an ADC map provides a purely parametric readout 
of the movement of water molecules in the examined tissue region(31). 
1.4 Imaging the penumbra 
Various imaging methods have been developed to enable the identification of the 
ischemic penumbra, ranging in their degree of accuracy from those attempting to 
determine tissue status absolutely, as with Oxygen-15 (15O) based PET tracers, to 
surrogate readouts such as hypoxia tracers 18F-Fluoromisonidazol ([18F]FMISO) 
and 11C-Flumazenil ([11C]-FMZ), and non-invasive DWI, perfusion weighred imag-
ing (PWI) and BOLD MRI.  The motivation behind seminal attempts to image the 
penumbra specifically were based on early methods, developed in the 1940s and 
50s, in which nitrous oxide or xenon-133 were employed to track regional blood 
flow dynamics in the context of functional activation of the brain. These methods 
subsequently became established for studies on AIS(33, 34).
1.4.1 Oxygen-15 PET provides gold standard 
15O based PET, pioneered in the 1970s, has been extensively used to identify and 
investigate the metabolic impairments of the ischemic penumbra, and  has pro-
vided major insights into the pathophysiology of AIS in animal models as well 
as in humans ((35-38), see (14)for review). Experimental studies on cats and 
non-human primates were able to establish that the recruitment of the penumbra 
to the ischemic core is a gradual process, and provided an in-vivo outline of the 
emergence of irreversible tissue damage following an acute loss of CPP. These 
discoveries prompted the understanding of ischemic injury as resulting not only 
from the severity of the perfusion deficit, but also from the length of time it is in 
play(39).  Moreover and significantly, investigations performed in the early 1980s 
were able to outline the hemodynamic and metabolic detorioration of severly 
8hypoperfused but viable tissue, the condition described as misery perfusion(17, 
40-43) and in which a reduction in CBF to 12–22 mL/100 g/min is coupled with 
metabolic impairment in the form of a ~ 40% elevation of OEF while CMRO2 is 
sustained more or less at physiological levels. These observations strongly indicated 
the presence of a time-dependent ischemic penumbra in human stroke patients. 
15O is a positron emitting radioisotope with a short half life of 123 s. Several 
methods for the examination of oxygen metabolism with 15O have been developed. 
The most established is the steady-state inhalation method pioneered in the early 
1980s(36, 44). In the steady-state method a continous inhaltion of 15O is utilized. 
Within approximately 10 min, the kinetics of the radiotracer will have settled into 
a steady-state between 15O being supplied to the brain through the arterial circu-
lation, the extraction of 15O to brain tissue and the subsequent wash-out of H215O 
resulting from cellular respiration. The accuracy  of the 15O inhalation method was 
improved by complementing it with the steady-state measurements of regional 
CBF. These employ an initial, continous inhalation of 15O-labeled carbon dioxide 
(C15O2) which is converted to 15O water (H215O) in the lungs and subsequently 
transported through arterial blood to the organ of interest, such as the brain. If the 
partition coefficient of water between blood/brain tissue and the H215O concentra-
tion in arterial blood are both known, a calculation of CBF is possible. The 15O 
inhalation method benefits from the possibility to correct for recirculating H215O 
and a mathematical model can be applied to determine regional OEF (14, 45). To 
increase accuracy, the method was refined(46, 47) to include also the inhalation 
of 15O-labeled carbon monoxide (C15O) which results in irreversbly radiolabeled 
red blood cells that can be used to measure CBV. 
The impact of 15O PET studies into the progress of AIS during the 1980s and 
1990s cannot be overstated, with investigations initialising and augmenting the 
understanding of the pathophysiological concepts that define the basis for experi-
mental and clinical strategies to date. These studies outlined for the first time the 
in vivo progression of acute cerebrovascular disease. 15O PET was used also to 
outline hemodynamic and metabolic signatures of CCH; examinations on patiens 
with chronic carotid occlusion showed extensive regions with decreased CBF, 
increased OEF but normal levels of CMRO2, consistent with persistent oligemia 
(14). Given that ischemic injury in the brain is a product both of the time and sever-
ity of a perfusion deficit, it is to be expected that oligemic tissue may transition 
into penumbra unless adequate blood flow is restored.The implementation of 15O 
PET remains the experimental gold standard of penumbra imaging. Nevertheless, 
due to major logistical drawbacks such as the very short half-life of 15O (123 s) 
it is highly unlikely that we will we see the routine application of 15O PET in the 
foreseeable future.
91.4.2 Perfusion Weighted Imaging in ischemic stroke  
With the emergence of high-field MRI during the 1990s, perfusion-MRI became 
a readily available alternative to logistically challenging 15O PET methods. PWI 
performed with CT or MRI is now a routinely used method for evaluating the 
severity and spatial distribution of blood flow deficits in AIS. We will focus on 
PWI obtained by MRI. To date, two methods have been established for the acqui-
sition of PWI with MRI. These are bolus tracking PWI, i.e the first-passage of a 
highly magnetic intra-venous contrast agent(48, 49)], commonly Gadolinium, and 
arterial spin labelling (ASL). We will focus on ASL-based PWI and two methods 
used in its acquisition. 
Continuous ASL employs magnetic labelling, tagging, of arterial blood through the 
application of an up to seconds long inversion RF pulse to the cervical arteries(50, 
51). The magnetic inversion of the protons contained in the blood reaching the 
brain causes a marginal T1-signal loss that is harnessed in a so-called tag-image, 
and which is subsequently compared to a non-tagged control. In Dynamic ASL 
(DASL), the effect of tagged blood on T1-signal is measured at several time points 
relative to the time of the inversion RF pulse. The benefits of collecting data at 
several different time points subsequent to labelling is it allows for a better estima-
tion of the biases produced by the T1- relaxation which occurs during the transit 
time of tagged proton. The transit time, also referred to as inflow time, is the time 
it takes for the tagged proton to travel from the tagging plane at the location of 
the cervical arteries to the imaging plane. 
Various hemodynamic parameters can be obtained from ASL PWI. Those included 
in the central volume principle (equation 1), in which blood flow is defined as 
the quotient of blood volume and the transit time of red blood cells through the 
vascular bed, are the most established.
(1)
CBF = CBVMTT
Since its emergence, PWI has been proposed as a potential method for the identi-
fication of the ischemic penumbra. The specificity of PWI has however remained 
inconsistent, with a general consensus regarding the correct interpretation of 
results still lacking. In part, this is caused by the continuous debate regarding the 
absolute blood flow thresholds separating the penumbra from irreversibly dam-
aged tissue, as well as from so-called oligemic tissue which is not at an immedi-
ate risk of infarction(52). In a systemic review performed by Bandera et al.(52), 
it was observed that mean values for relevant blood flow thresholds are largely 
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consistent with those in experimental studies, however, results deviated to such 
a degree that further validation was deemed required to increase the diagnostic 
value of PWI. Moreover, several technical issues, such as a lack of standardized, 
methodological protocols and observer unreliability have limited the use of PWI 
as a stand-alone diagnostic tool for AIS. Due to these issues, the implementation of 
PWI has largely been as a component of composite imaging regimes, in particular 
the DWI/PWI mismatch surrogate of the ischemic penumbra(2).
1.4.3 DWI/PWI mismatch as a surrogate of the penumbra 
The current consensus regarding the progression of AIS describes the time-depend-
ent and continuous expansion of irreversible damage into regions of ischemic 
penumbra(53, 54). The restoration of blood flow to the hypoperfused areas sur-
rounding the ischemic core, the DWI/PWI mismatch, initially proposed in the 
mid- 1990s(2, 55), has been proposed as a surrogate measure of the penumbra. 
Although we will focus of DWI/PWI as measured with MRI, a corresponding 
measurement is available using CT where a perfusion image is compared to a non-
contrast image of the ischemic lesion. Lesion expansion occurs predominantly in 
patients with large mismatches in the early phase of AIS and is present in around 
70% of patients(32, 56, 57). The DWI/PWI mismatch as a surrogate of the ischemic 
penumbra is underpinned by observations that the restoration of blood flow inhibits 
DWI lesion expansion, and by the rapid resolution of neurological deficits found 
following reperfusion in patients with large mismatch regions(58, 59). Over the 
last decade, DWI/PWI mismatch has been successfully implemented to define the 
ischemic penumbra in several clinical studies(8, 60-63).
An important question of specificity has been directed at the DWI/PWI mismatch 
as a surrogate marker of the penumbra. Firstly, there is a currently, as pertaining to 
PWI, a lack of methodological uniformity between centers. This issue is accentu-
ated by the fact that the estimated size of the penumbra varies according to which 
perfusion parameter is used.     Secondly, as mentioned previously, the formation 
of ischemic injury in tissue results not from the degree of perfusion impairment 
alone, but rather from the severity as well as the duration of a perfusion deficit. 
This means that PWI does not provide a direct measurement of tissue status, and 
there is a risk of overestimating the amount of penumbra contained in the DWI/
PWI mismatch(64).  Regardless of the lack of a general consensus on how to best 
perform and interpret combined DWI and PWI examinations, there are strong 
arguments for the clinical relevance of DWI lesion expansion at the expense of 
surrounding hypoperfused regions. Several studies have observed highly variable 
degrees of ischemic lesion growth in AIS, with slower growth linked to a higher 
potential to form a significant penumbra and an improved clinical outcome fol-
lowing acute intervention and reperfusion (65-67). 
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1.4.4 BOLD MRI 
BOLD MRI(68) can be used to examine the metabolic impairment of tissue and 
has been proposed as an alternative to 15O PET and DWI/PWI mismatch for the 
identification of penumbra (21).  The BOLD methodologies applied in experimen-
tal stroke research are various, and largely defined by the capabilities of different 
centres to obtain readouts of hemodynamic parameters.
The basis for BOLD methodology is the difference in magnetic susceptibility of 
oxygenated and deoxygenated (dHb) hemoglobin, which are respectively weakly 
diamagnetic and strongly paramagnetic(68). Magnetic susceptibility is a dimension-
less property which describes the degree of magnetization of tissue when exposed to 
a magnetic field. In AIS and CCH, the OEF of the penumbra becomes elevated(69). 
OEF elevation increases the fraction of dHb in the venous blood that is drained from 
affected tissues. The accumulation of dHb creates mesoscopic magnetic field inho-
mogeneities which increase the transverse relaxation rates R2 (1/T2) and R2* (1/
T2*) of examined tissues. A change in tissue OEF is therefore detectable by employ-
ing an MRI sequence sensitive to transverse relaxation, such as gradient echo T2*. 
If both R2 and R2* are known, the effect of microscopic tissue decay, contained in 
R2, can be subtracted from R2* to produce R2′ according to equation 2. R2′ more 
exclusively measures the effect of the concentration of dHb in venous blood and is, 
considering that R2 has been removed, not as affected by manifest pathology such 
as vasogenic edema or inflammatory gliosis(70, 71). Please see Figure 2 for char-
acteristic examples of R2, R2* and R2′ in an animal subject to M2CAO.    
(2)
R2* = R2 + R2'
1.4.5 Determining Oxygen Metabolism with Quantitative BOLD 
The quantitative BOLD (qBOLD) approach was initially developed in the 2000s(72). 
A commonly accepted model developed by Yablonskiy & Haacke defines the rela-
tionship between R2  relaxation time, venous dHb fraction and venous blood vol-
ume (CBVv) in a network of randomly oriented cylinders(73). As a rule, qBOLD 
regimes now apply T2* gradient echo (GE) as well as T2-weighted spin echo (SE) 
sequences as readouts of magnetic susceptibility, with the susceptibiliy of the exam-
ined tissue proportional to the concentration of dHb. However measuring tissue 
susceptibiliy with T2* and T2 is not enough to reliably estimate OEF or CMRO2, 
considering that transverse relaxation is affected also by tissue CBV, CBF, Hct, 
as well as other contributing factors (74). In order to calculate the regional OEF, 
it is thereofore necessary to differentiate the susceptibility contribution made by 
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dHb located in the venous compartment from that of dHb contained in the arterial 
compartment. While the latter is easy to assess by combining a non-invasive pul-
soximetry with a Hct blood test, calculation of the dHb concentraion of the venous 
compartment is more cumbersome and requires a measurement of CBV, which is 
acquired either by ASL or by the use of highly magnetic contrast agent such as 
iron-oxide particles. A partition coeffecicient constant can then be factored in to 
approximate the proportion of CBVv from total CBV. Once an approximate value 
of CBVv has been determined, OEF can be calculated according to equation (3): 
(3)
OEF = R'2
CBVv Δχ  Hct B0 γ4л
1
3
In this model (2), Δχ0 describes the susceptibility difference between fully oxygen-
ated and fully deoxygenated blood = 0.264 ppm35, Hct is hematocrit blood fraction, 
B0 is magnetic field strength and γ is the gyromagnetic ratio for the proton nucleus 
= 2.68 x 108. The oxygenation fraction of arterial blood is assumed to be 100%, i.e 
1/1 (74-76). Provided CBF is also known, once tissue OEF has been determined 
it can be used to calculate CMRO2 according to equation 4(75),  
(4)
CMRO2 = Crbc CBF rOEF ϒa Hct
in which Crbc is the oxygen carrying capacity of red blood cells (CRBC = 0.493 ml 
O2/ ml RBC), Ya is the oxygenation fraction of arterial blood and CBF is meas-
ured in ml/ 100 g/ min. 
Figure 2. R2, R2* and R2′ images from a single animal. The images are from an exami-
nation performed during M2-segment occlusion of the middle cerebral artery (M2CAO). 
Images are from the same location in the brain. The animal was included in paper III. 
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1.4.6 Quantitative BOLD in acute ischemic stroke 
qBOLD MRI has the capacity to detect metabolic impairments in AIS, thereby 
identifying tissue-at-risk. Several studies have implemented the qBOLD approach 
in animals and humans (75-79). In a study from 2014(78), Christen et al. observed 
a correlation between areas of decreased oxygen levels as defined by MRI and 
ex-vivo examination with hypoxia specific biomarkers. Other studies using MRI 
sequences sensitive to transverse relaxtion have demonstrated how perfusion deficits 
correlate to increased OEF in AIS patients(77, 80). Although highly promising, the 
qBOLD technique also has challenges such as the need for several examinations 
and longer examination times than what is necessary with CT. 
1.5 Cellular hypoxia in ischemic stroke  
Hypoxia occurs when the amount of oxygen supplied to cells becomes inadequate 
to sustain normal physiological functions. AIS causes ischemia which in turn will 
result in hypoxia in affected cell populations. In worst case scenarios, hypoxia 
may result in the cessation of cellular ATP production, leading to an accumula-
tion of cytotoxic edema and ultimately necrosis(81). Considering the potential of 
a single examination capable of identifying the penumbra there have been sev-
eral attempts to develop radiotracers with the capacity to assess tissue hypoxia in 
ischemic regions. 
1.5.1 PET imaging with tracers for hypoxia  
Radiotracers for hypoxia are especially desirable given that no workable method 
for measuring tissue oxygenation exists in clinical settings. While 15O-PET provides 
a gold standard for the imaging of oxygen metabolism (see above), the method is 
invasive and unpractical given the short half-life of 15O (123 s). Other methods exist 
but are conditioned by their own limitations. BOLD MRI requires a combination 
of several different examinations. The polargraphic electrode technique is capable 
of electrochemical detection of oxygen concentrations but is highly invasive and 
limited to superficial structures(82). Near infrared spectroscopy is also limited to 
superficial structures(83). 
The 1990s saw the emergence of hypoxia specific radiotracers that benefited from 
not requiring the arterial blood testing necessary for steady-state 15O imaging. Out 
of these, the central benzodiazepine receptor ligand [11C]FMZ and the nitroimida-
zole derivative [18F]FMISO(84) have been established in animal studies and used 
in studies on human stroke patients. 
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1.3.1.1 [11C]-FMZ
[11C]FMZ binds to the exclusively neuronal and ischemia-sensitive GABAA recep-
tor which is abundant in the cerebral cortex. Early observations found decreased 
[11C]FMZ activity in regions of neuronal death following temporary ischemia in 
baboons(85). Experiments on cats subject to MCA occlusion provided encourag-
ing results with regions displaying defects in [11C]FMZ binding closely related to 
areas with severely depressed oxygen metabolism(86). These results were later 
reproduced in human ischemic stroke patients, with the absence of [11C]FMZ 
binding found to occur in areas of severe CMRO2 decline(87). A subsequent clini-
cal study, investigating the effects of interventional therapy of AIS, reported that 
hypoperfused tissue could stand to benefit from reperfusion only as long as [11C]
FMZ binding was reduced no more than 3.4 times the normal uptake(88). The 
experimental use of [11C]FMZ  has in recent years mainly focused on the moni-
toring continued neuronal loss in the subacute and chronic phase of AIS(89, 90).
[18F]FMISO and [64Cu]CuATSM
[18F]FMISO diffuses freely across cell membranes and subsequently undergoes 
single-electron reduction, transforming into a potentially reactive species. In viable 
cells with physiological levels of oxygen pressure, it will momentarily be re-oxi-
dized before diffusing back into the extracellular space. During cellular hypoxia 
re-oxidization is prohibited which results in [18F]FMISO undergoing additional 
reduction and binding irreversibly to the intracellular compartment (91). Early 
studies found [18F]FMISO activity surrounding infarcted regions in AIS patients 
during the first 48 h after ictus. The areas of high [18F]FMISO accumulation were 
interpreted as representing the ischemic penumbra, motivated by the fact that [18F]
FMISO does not access cells that have undergone infarction regions of increased 
[18F]FMISO uptake did not reappear in follow-up examinations performed between 
days 6-11(92), indicating that the tissue had either perished or resolved back into 
metabolic homeostasis. [18F]FMISO has since been employed to illustrate how 
irreversible damage spreads from the center to the periphery of regions suffering 
ischemia in stroke patients (93). Similar results have been found in animal stroke 
models (94, 95). The [18F]FMISO-similar nitroimidazole tracer [18F]FRP170 has 
been used to reveal hypoxia in regions of increased OEF in cases of CCH(96). 
It is now understood that [18F]FMISO activity in ischemic tissue declines over 
time(97). Nevertheless, question marks remain over the specificity of [18F]FMISO 
for tissue-at-risk. A validation attempt performed in a limited number of AIS 
patients observed that [18F]FMISO activity did indeed spike as perfusion declined 
to levels consistent with those seen in penumbra. However, increased tracer activity 
was found also to overlap with irreversibly damaged tissue as identified by DWI 
and with non-symptomatic tissue without any perfusion deficit (98). Moreover, 
a major drawback of [18F]FMISO is the necessity of lengthy examinations due to 
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the substantial time required for adequate accumulation in hypoxic cells (> 2 h). 
This makes the clinical application of [18F]FMISO appropriate in cases of CCH 
and in the subacute rather than the acute phase of ischemic stroke. 
 Cu-diacetyl-bis(N4- methylthiosemicarbazone) ([64Cu]CuATSM)(99) is a hypoxia 
radiotracer that is considerably less explored than [18F]FMISO in the context of 
AIS. Similarly to [18F]FMISO, it undergoes passive diffusion into the intracellular 
compartment where it is reduced to Cu(I)-ATSM. It is subsequently reoxidized 
back to Cu(II)-ATSM, facilitating wash out, as long as the intracellular concen-
tration of oxygen is normal(99). If the cell is subject to hypoxia, however, the 
Cu(I)-ATSM compound remains in the intracellular compartment, where Cu(I) 
undergoes further reduction as well as subsequent reactions which leaves it irre-
versibly trapped within the cell(100, 101). [64Cu]CuATSM is especially interesting 
because it requires significantly less accumulation time than [18F]FMISO, poten-
tially allowing its use in the acute phase of AIS (89). The tracer has already been 
used with promising results in imaging of tumor hypoxia (102-104), and also in 
ischemia-caused myocardial hypoxia(101, 105) as well as in AIS(106). 
1.6. Acute neuroinflammation in ischemic stroke  
An acute inflammatory response is a major component of the pathophysiological 
processes that follow AIS. Neuroinflammation has been implicated in the emer-
gence of secondary injury after stroke, and in the degree of the resulting brain 
damage(107-109). With AIS treatment now capable of achieving significant neu-
rological recovery, understanding inflammatory responses after AIS is important 
to further optimize the treatment of stroke patients.  Acute neuroinflammation 
has been described as double-edged sword with potentially both beneficial and 
detrimental effects on clinical outcome (110-112). Long-term consequences of the 
inflammatory response seem to differ depending on the underlying pathology that 
causes it. In the context of AIS the acute neuroinflammatory response is typically 
characterized by early the activation of resident microglia and by the large-scale 
infiltration by blood-borne macrophages. It is also made up by the recruitment 
and activation of blood-borne leukocytes, specifically neutrophils and monocytes, 
and of the morphological changes in astrocytes. 
Microglia are the resident phagocytes of the central nervous system and constitute 
as much as 10% of the total cell population of the brain. In physiological condi-
tions, they maintain a ramified, resting phenotype highly dissimilar to that of the 
blood-borne macrophage; cerebral insult, however, will initiate a rapid structural 
remodeling resulting in the amoeboid morphology of the phagocytic microglia 
(113, 114). In tandem with microglia activation, the astrocyte cell population will 
initiate reactive gliosis in response to ischemic injury. Reactive gliosis permits 
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the formation of glial scar tissue throughout the rim of injured brain regions(115). 
Although the clinical significance of neuroinflammation in AIS is not yet fully 
understood, what is clear is that it is a major pathophysiological component during 
the acute to subacute phases of AIS. Neuroinflammation has been implicated in 
the emergence and severity of secondary brain injury(113). It may have negative 
consequences comparable to those attributed to the inflammation and subsequent 
tissue remodeling that follows myocardial infarction(116).
1.6.1 Profiling neuroinflammation with immunohistochemistry 
Histological immunohistochemistry (IHC) analysis is the gold standard for exam-
ining neuroinflammatory processes. In microglia and astrocytes, the process of 
reactive gliosis entails the upregulation of several biomarkers that are readily 
employed for IHC; the activated microglia increases the amount of complement 
type 3 receptor Cd11b, which binds to the monoclonal antibody (MAB) Ox42(113). 
The debridement of necrotic material performed by mononuclear phagocytic 
cells results in the formation of phagolysosomes that are recognized by the MAB 
ED1(117). Anti-glial fibrillary acidic protein (GFAP) is used to examine the activ-
ity of astrocytes. However, microglia and monocytes differentiate  from the same 
mesodermal/mesenchymal progenitor, with microglia immigrating to and seeded 
within the mammal brain during early fetal development(118). This entails an all 
but absent distinction in the surface marker profile between macrophages and 
the activated microglia phenotype(119), and poses a challenge for any attempt to 
distinguish between the cell types with IHC or PET imaging. 
1.6.2 Imaging neuroinflammation with PET  
Neuroimaging is capable of examining the inflammatory response that occurs in 
the subacute and chronic phases of ischemic stroke. When compared to ex-vivo 
analysis of neuroinflammatory processes, it has the obvious advantage of allow-
ing in-vivo examinations and thereby longitudinal study designs. There are spe-
cialized techniques for the identification of inflammatory cells with PET in the 
form of translocator protein 18 kDa (TSPO) specific radiotracers. The expression 
of TSPO, previously known as the peripheral benzodiazepine receptor (PBR), 
is upregulated in microglia and astrocytes in conjunction with reactive gliosis. 
TSPO upregulation within microglia and monocytes was initially observed inside 
ischemic lesions by Myers et al.(120), and was subsequently documented also in 
the peri-infarct regions(71, 121). TSPO upregulation has since been found also 
in astrocytes present along the peri-infarct rim (122). The substantial upregula-
tion of TSPO in these cell types following various cerebral pathologies has been 
harnessed in PET employing radioligands against TSPO as a routine technique 
for imaging of acute neuroinflammation in experimental settings. Several TSPO-
17
radioligands have been developed for this purpose, with [11C]PK11195 the most 
established and most commonly used. The various inherent drawbacks of [11C]
PK11195, including poor signal-to-noise ratio and the high degree of non-specific 
binding(123), have prompted the development of so-called second-generation 
TSPO radioligands such as [18F]FEPPA, [11C]DPA-714 and [11C]PBR28. Among 
these [11C]PBR28 has improved on the disadvantages of [11C]PK11195 and has 
been employed in several pre-clinical studies including small animal models of 
experimental cerebral ischemia(71, 124). 
1.7 Animal ischemic stroke models   
Experimental research performed in animal models has been crucial to our current 
understanding of AIS pathophysiology. The conventional middle cerebral artery 
(MCA) suture occlusion model (MCAO)(125) has become the reliable workhorse 
of experimental AIS research. However, rather than simulating AIS cases suitable 
for revasculatory treatment, the MCAO model mimics the severe perfusion impair-
ment and inhibition of collateral blood that occurs in cases of malignant MCA 
infarction(27). Malignant MCA infarction is characterized by extensive regions of 
irreversible damage that rapidly expand at the expense of penumbra tissue. As in 
malignant MCA infarction, the irreversible damage caused by the MCAO model 
is extensive and carries a high likelihood of hemorrhagic complications. 
The MCAO model is performed by inserting a suture into the internal carotid 
artery through a transection of the external carotid artery (ECA). Although the 
MCAO model has been modified since first described, fundamental problems 
remain, and a significant contribution to the extensive infarcts seen in the MCAO 
model is the inhibition of collateral flow through the network of LMAs that con-
nect the supply regions of the major arteries of the brain. In the MCAO model, a 
filament fills out the lumen of the anterior cerebral artery (ACA), where the tip of 
the filament is positioned. This results not only in the inhibition of flow through 
the MCA, but also in a severe reduction of collateral blood flow through virtually 
all LMAs since the filament obstructs flow both in the ACA and posterior com-
municating artery (Pcom). While in humans the Pcom is slender, in the rat, the 
Pcom is a major vessel, arising from the internal carotid artery, and forming an 
anastomosis with the smaller posterior cerebral artery (PCA) that originates from 
the basilar artery (126). In rats, the Pcom appears to continue beyond its junction 
with the PCA, providing a direct vascular channel between the internal carotid 
artery and the caudal regions of the cerebral hemisphere. Branches from the Pcom 
supply subcortical structures such as the hypothalamus. Distal to the junction of 
the PCA and the Pcom, the resulting vessel in the majority of animals ramifies into 
branches supplying the hippocampus and caudal regions of the midbrain, as well 
as providing leptomeningeal anastomoses with collateral blood flow(127). (127). 
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The MCAO model consequently mimics a terminal carotid T occlusion (125, 128) 
with the severe disruption of collateral blood flow typical of malignant infarc-
tions (129).  Another significant disadvantage of the MCAO model results from 
the ECA transection used to introduce the suture to the cerebral vasculature. This 
procedure produces ischemic injury to muscles used for mastication and swallow-
ing, inevitably causing weight loss and suffering in the animal. Furthermore, the 
ischemic injuries caused to the hypothalamus are prone to produce hyperthermia 
and disturbance in water homeostasis which are not phenomenons associated with 
human AIS(125). 
1.7.1 Middle cerebral artery M2-segment occlusion model in rat 
(M2CAO) 
The papers included in this thesis use the M2-segment occlusion ischemic stroke 
model in rat (M2CAO). The M2CAO model was developed by Arnberg et al. 
to improve the translational value of animal AIS research(130) and has several 
advantages to the conventional MCAO model. In short, M2CAO is an endovas-
cular method, performed by guiding a small microwire into the M2 – segment of 
the MCA under guidance of fluoroscopy imaging. In contrast to the conventional 
MCAO, the M2CAO model causes only a marginal CBF reduction in the PCA 
supply region, and does not reduce the perfusion of the ACA supply region to an 
extent causing ischemic injury, making it more similar to the majority of clini-
cal strokes (carotid T-occlusion and malignant infarction being exceptions). The 
M2CAO model effectively simulates human AIS cases suitable for intervention, 
in that the initial volume of irreversible damage within brain regions subjected 
to M2CAO is limited and surrounded by large regions of potentially salvageable 
tissue-at-risk(70). 
The M2CAO model also has the advantage of minimally invasive retraction of 
the microwire from the M2-segment of the MCA, which achieves reperfusion. 
Reperfusion can be performed without manipulating the body of the examined 
animal. This is beneficial when performing imaging studies because examinations 
can be performed both during M2CAO and after reperfusion without the need to 
remove the animal from the scanner. Also, in stark contrast to the suture MCAO 
model, animals subjected to M2CAO are not subjected to the suffering caused 
by ischemic injuries to muscles involved in mastication and swallowing, or to 
the detrimental effects of hyperthermia in addition to near hemispheric ischemic 
injuries(130). 
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2. AIMS OF THE THESIS 
The aim of the thesis was to investigate tissue pathophysiology in AIS as mod-
elled by M2CAO, and to use these findings to develop and improve methods for 
the identification of the ischemic penumbra through imaging with MRI and PET. 
The specific aims of each paper were: 
(I) To investigate the neuroinflammatory response in the acute and subacute 
phases of transient M2CAO with the radiotracer [11C]PBR28, and to 
validate [11C]PBR28 against the gold standard of ex-vivo IHC analysis.
(II) To profile the emergence and expansion of irreversible injury at the 
expense of ischemic penumbra as defined by DWI/PWI mismatch 
MRI during M2CAO.  
(III) To assemble a MRI protocol capable of investigating the oxygen 
metabolism of ischemic tissue, and to use this protocol to identify the 
ischemic penumbra during M2CAO. Then, to compare the MRI pro-
tocol with the DWI/PWI mismatch protocol used in paper II. 
(IV) To compare the effectivity of PET tracers [18F]FMISO and [64Cu]
CuATSM in identifying tissue hypoxia resulting from M2CAO. 
Subsequently, to investigate the effects of hypoxia in ischemic tissue 
using ex-vivo IHC analysis. 
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3. METHODOLOGICAL CONSIDERATIONS 
This thesis is the result of data produced using several methodological modalities. 
These include fluoroscopy (papers I-IV), MRI (I-IV), PET (I, IV) and IHC (I, IV). 
Detailed descriptions of methodological procedures concerning acquisition and 
processing of data are available in the original manuscripts. This section, while 
containing summary descriptions, focuses instead on particular considerations 
behind the choice of methods.  
3.1 Study designs and analysis  
3.1.1 Paper I 
26 animals were included in the study. Animals were subjected to 90 min M2CAO. 
Out of these, six animals underwent longitudinal PET examinations with the TSPO 
targeting radiotracer [11C]PBR28. These examinations were performed in order 
to profile the emergence and progression of acute neuroinflammation following 
AIS. Animals were examined with MRI in proximity to PET scans. Examinations 
were performed on day 1, day 4, day 7 and day 14 after 90 min M2CAO. All 26 
animals were included in ex-vivo IHC analysis in order to validate the results of 
the [11C]PBR28 examinations and to expand the profiling of the neuroinflamma-
tory response. Specifically, the IHC analysis quantified the presence of monocytes/
microglia exhibiting TSPO upregulation in and around the ischemic lesion. The 
analysis also profiled the formation of glial scar tissue by activated astrocytes 
exhibiting TSPO upregulation in the tissue immediately surrounding ischemic 
lesions. A separate ICH analysis profiled the progression of debridement performed 
by phagocytic such as macrophages and activated microglia in ischemic lesions. 
Antibodies used for IHC were Cd11b for monocytes/microglia (ab33827, Abcam, 
Cambridge, UK); GFAP for astrocytes (MAB3402, Cell Signaling Technology, 
Danvers, MA, US); Cd68 for phagocytic cells (Ed-1, MAB1435, Millipore), NeuN 
for neuron nuclei (ABN78, Millipore, Bedford, MA) and EPR5384 for TSPO 
(ab109497, Abcam, Cambridge, UK). 
Analysis
The activity of [11C]PBR28 was measured in ischemic lesion regions of inter-
est (ROIs) outlined on T2 images acquired on day 1 after M2CAO. [11C]PBR28 
activity in these regions was quantified as standardized uptake values (%SUV) 
which were normalized for injected dose and animal weight and were compared 
to contra lateral control regions. PET data was analyzed in (PMOD Technologies 
Ltd., Zurich version: 3.3). Student´s two tailed paired t-test was used to test for 
statistical significance. 
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The IHC analysis consisted of two separate data sets. In the first data set, the 
ischemic lesion ROI was defined as regions largely devoid of viable GFAP+ 
astrocytes. Cd11+ and GFAP+ cells, with or without TSPO co-localization, were 
counted on either side of the glial rim surrounding the ischemic lesion (Metaviewer 
software, Metasystems). In the second set, Cd68+ cells were quantified within 
ischemic lesions. The borders of the ischemic lesion were outlined by the pres-
ence of neurons exhibiting pyknotic morphology consistent with ischemic injury. 
ImageJ (National Institutes of Health, Maryland, USA) software was used to count 
cells within the ischemic lesions. One-way ANOVA corrected for multiple com-
parisons through Tukey post hoc test was used to test for statistical significance 
in both IHC data sets. 
3.1.2 Paper II 
25 rats were divided into three groups subjected to Short (90 min), Intermediate 
(180 min) or Extended (600 min) M2CAO (Figure 3). M2CAO was followed by 
reperfusion. Animals were examined repeatedly every 30 min with T2, DWI and 
PWI during M2CAO and reperfusion. Animals belonging to the Extended group 
also underwent follow-up examinations on the following day. The assembled data 
was used to profile injury progression in the hyperacute and acute phase of AIS 
as modelled by M2CAO. 
Figure 3. Study design of paper II. 
Analysis; 
ImageJ and ITK-SNAP software were used for ROI segmentation(131). Please see 
Figure 4 for visual descriptions of ROIs. In order to profile the severity of ischemic 
injury, the progression of ADC decline and T2WI signal increase, as well as lesion 
volume progression, was measured across the repeated examinations performed 
in each animal. The data was fitted to a mixed effects statistical model which is 
a standard method for the analysis of repeated measurements data and uses the 
modelling time as a regression variable. This was especially appropriate in view 
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of our study design. The method allowed us to incorporate all the collected data 
points, thereby strengthening the quality of the analysis. As well as tracking the 
severity of ischemic injury, we documented CBF in four regions that will now 
be described: The ischemic core ROI (IC) consisted of regions exhibiting ADC 
decline and was delineated in the first examination performed after reperfusion. 
IC ROIs were subsequently transferred to the CBF map from the first examination 
after M2CAO in the same animal, and used to delineate the penumbra ROI which 
matched the DWI/PWI mismatch. Supply regions of the ACA (supero-medial 
cortex) and the PCA (thalamus, parts of the hypothalamus) were also outlined 
into individual ROIs. Regional CBF levels were examined for correlations using 
Spearman coefficients. Longitudinal CBF of the IC and PEN were also compared 
to control regions in the healthy hemisphere using paired students t-tests. 
Figure 4. Regions of interest (ROIs) used in paper II. (A) Ischemic core regions (red) 
seen in apparent diffusion coefficient maps (A) and T2-weighted images (B) (C) Cerebral 
blood flow (CBF) maps. (D) CBF maps overlain with ADC maps. ROIs used to examine 
the CBF of the Ischemic Core (cyan), penumbra (white), anterior cerebral artery supply 
regions (purple), and posterior cerebral artery supply region (yellow). 
3.1.3 Paper III
20 animals were included in the study prior to exclusions. Animals were subjected 
to ~ 80 min M2CAO and were imaged with the imaging protocol shown in Figure 
5 during M2CAO and after reperfusion. The protocol included: DWI to outline 
irreversible damaged, ischemic core regions; multi echo multi slice (MEMS) and 
Multi gradient echo 3D sequences (MGE3D) to obtain R2 and R2*, respectively; 
continuous ASL to calculate CBF and; turbo DASL (T-DASL) to determine CBV. 
Readouts were combined in a qBOLD regimen and used to determine levels of 
OEF and CMRO2 in the ischemic tissue of animals subjected to M2CAO. 
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Figure 5. Imaging sequence used in paper III. 
Analysis 
The ischemic core ROI (IC) was manually traced in ADC-maps and defined as 
regions with an apparent decrease in ADC. IC ROIs were subsequently transferred 
to CBF and OEF maps where, respectively, regions of perfusion deficit as well as 
OEF elevation were outlined in tissue not included in the IC. The volume of the 
ischemic core- OEF elevation (IC-OEF) mismatch was compared to the volume 
of ischemic core-CBF perfusion deficit (IC-CBF) mismatch.
We also examined effects of M2CAO and reperfusion on the absolute levels of OEF 
and CMRO2 in severely ischemic but still viable tissue. These regions were out-
lined in CBF maps as tissue with normal perfusion but CBF levels of 12–22ml/100 
g/min which is consistent with levels attributed to the penumbra (132). Healthy 
contralateral regions were used as controls. Student´s two tailed paired t-test was 
used to test for statistical significance. 
3.1.4 Paper IV
Animals underwent ~ 2 h M2CAO and were subsequently examined with either 
[18F]FMISO  (n=12) or [64Cu]CuATSM  (n= 6). Animals were injected with pimo-
nidazole hydrochloride (Hypoxyprobe-1TM, Hypoxyprobe Inc., Burlington, MA, 
USA) approximately 30 min before the start of M2CAO. The [64Cu]CuATSM 
group was also examined with DWI MRI to enable an independent confirmation 
of ischemic lesions. Animals in the [18F]FMISO group were not, however, exam-
ined with MRI due to a positive correlate for ischemic injury already achieved 
by the use of pimonidazole which corresponds to [18F]FMISO uptake. In addition 
to in-vivo PET, ICH immunofluorescent analysis was performed with antibod-
ies for hypoxia (pimonidazole), neuronal nuclei (NeuN) and astrocytes (GFAP). 
The objective of the IHC analysis was to determine levels of hypoxia in neurons 
and astrocytes within ischemic regions. The experimental protocol is illustrated 
in Figure 6. 
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Analysis
In the [18F]FMISO group, hypoxic regions of interest were manually outlined 
around tissue exhibiting an apparent uptake in [18F]FMISO within the cortical 
hemisphere subjected to M2CAO. A similar analysis was performed in the ani-
mals examined with [64Cu]CuATSM, but here ROIs were defined according to 
ischemic core lesions present in DWI MRI. Control regions were placed in the 
contralateral cortex.  
The PET data was quantified as SUV%. The ICH data was analyzed using an 
in-house ImageJ script. The script analyzed the intensity levels of pimonidazole 
within astrocytes and neurons present in hypoxic regions in the cortical regions 
subjected to M2CAO. Healthy cells located in control regions of the contra lateral 
hemisphere were used as controls. Student´s two tailed paired t-test were used to 
test for statistical significance. 
Figure 6. The experimental protocol used in paper IV.  
3.2 Animals and ethical considerations (Papers I-IV) 
All animal experiments were performed following the guidelines 
of the Swedish National Board of Laboratory and the animal welfare board of 
Karolinska Institutet. Experiments adhered to protocols approves under a protocol 
approved by the Ethics Review Board of Northern Stockholm, Sweden, and to the 
ARRIVE guidelines of animal research. 
In all, 89 naive, male Sprague-Dawley (SD) rats weighing 300-450 g were used in 
papers I-IV. Animals were subjected to M2CAO with durations 90 min (paper I-II), 
80 min (paper III) and 110 min (paper IV). In paper II, two subgroups of animals 
were subjected to significantly longer M2CAO durations of 180 min (n=8) or 600 
min (n=7). In the longitudinal study design used in paper I, the M2CAO model 
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caused only a limited amount of suffering for the animal. Animals received gen-
eral anesthesia with an Isoflurane/air mixture, as well as a local anesthetic at the 
point of incision in the tail of the animal. Vital signs were monitored throughout 
surgical procedures and throughout imaging examinations with MRI and PET. 
Injections of PET radiotracers were performed through a cannula inserted into 
one of the tail veins. Animals were sacrificed through decapitation while in deep 
general anesthesia.  
3.3 The use of the M2CAO model (Papers I-IV) 
Detailed surgical procedures of the M2CAO model have been previously 
described(130). The procedure was performed using X-ray fluoroscopy (Philips 
Allura Xper XD20 Interventional X-ray system, Philips Medical Systems) (Figure 
7.A). A 0.007-inch microwire (Hybrid; Balt Extrusion, Montmorency, France), 
sheeted inside a 0.020-inch microcatheter (Ultraflow; Covidien, Mansfield, MA, 
USA), was introduced in the proximal ventral tail artery. The microcatheter was 
advanced to the proximal descending aorta. The tip of the microwire was subse-
quently navigated and positioned in the M2 segment of the MCA, causing occlu-
sion (Figure 7.B). The M2CAO model was used for the many benefits described 
above. Foremost the M2CAO model was designed to increase the translational 
value of experimental AIS by replicating the pathophysiology and the circulatory 
impairment present in those AIS patients who are suitable candidates for acute 
intervention(130). These include the he sustained functionality of LMAs which 
enables the formation of significant regions of hypoperfused yet viable tissue 
adjacent to the ischemic core, i.e large DWI/PWI mismatch regions. 
In paper II, using the M2CAO model enabled us to examine the spread of the 
ischemic core at the expense of the DWI/PWI mismatch as imaged with MRI. In 
paper III, we were able to measure the size of regions with increased OEF and 
compare it with the size of the DWI/PWI mismatch. In paper I, a longitudinal study 
design was used to examined the neuroinflammatory reaction during the first 14 
days after M2CAO. In paper II, follow up examinations were performed on day 
1 after M2CAO in a subgroup of animals. It is our opinion that the quality of the 
results obtained in these studies was possible because of the limited neurologi-
cal damage incurred by animals subjected to M2CAO, as well as by avoiding the 
detrimental side effect produced by the MCAO suture model. 
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Figure 7. A: The Philips Allura Xper XD20 Interventional X-ray system, Philips Medical 
Systems, used to perform middle cerebral artery M2-segment occlusion (M2CAO) in rat. 
B: Fluoroscopy image of the head of a rat (sagittal projection). A guidewire has been placed 
in the M2 segment causing M2CAO. 
3.4 Magnetic resonance imaging (Papers I-IV) 
MRI was used in paper I-IV. MRI was used due to its versatility and capacity to 
produce high resolution images of anatomy (T1), vasogenic edema (T2), cytotoxic 
edema (DWI), perfusion (PWI), as well as tissue oxygenation (T2*). In papers 
II-IV, animals were scanned in a 9.4 T magnet (Varian, Yarnton, United Kingdom) 
during M2CAO and after reperfusion. In paper I, animals were scanned in a Mediso 
nanoscan PET/MRI (Mediso Medical Imaging Systems Ltd. Budapest, Hungary) 
on day 1, day 4, day 7 and day 14 after M2CAO. Animal vital signs were moni-
tored throughout MRI examinations. 
3.4.1 Imaging irreversible tissue damage – T2WI and DWI 
(Papers I-IV) 
T2WI was used to identify irreversibly damaged tissue through the presence of 
vasogenic edema which results from blood brain barrier breakdown (papers I, II). 
DWI was used to identify the cytotoxic edema and thereby the tissue damage which 
appears very rapidly after M2CAO (papers II-IV). While T2WI is not sensitive 
enough to detect the emergence of irreversibly damage in the hyperacute phase of 
AIS, it is well suited for the detection of tissue injury in the subacute to chronic 
phases. The use of DWI was motivated by the fact that it is the most sensitive 
method available for the detection of tissue injury in the hyperacute phase in-vivo. 
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DWI was acquired by multi-slice three-shot spin-echo echo-planar imaging. 
Repetition time (TR): 3 s, echo time (TE): 25 ms, field of view (FOV) of 32 x 
32 mm, matrix size of 96 x 96 zero filled to 128 x 128 resulting in an in plane 
resolution of 256 μ m. Diffusion gradient duration (Δ): 2.3 ms, diffusion gradient 
separation (δ): 6.5 ms. Diffusion sensitizing gradients were applied along 12 direc-
tions with a b value = 1000 s/mm2 and a control image collected twice with the 
diffusion sensitizing factor b = 0. ADC-maps (mm2 /s) were calculated from the 
collected data. In paper I, T2WI was acquired through a fast spin echo sequence. 
In paper II & IV, T2WI was acquired with the same technical specifications listed 
above for DWI. 
MEMS (paper III) 
In paper III, T2WI was acquired through a multi-echo-multi slice sequence (MEMS) 
with 16 evenly spaced echoes with TE 6.94-110.98 ms in order to acquire quan-
titative T2-maps. The use of MEMS was motivated by the fact that sequences 
with a single TE would not have allowed us to determine the contribution to sig-
nal intensity arising from effects caused by flip angel, proton density, saturation 
effects from T1, etc. By using MEMS, it was possible to calculate the voxel wise 
time of T2-decay. MEMS data was processed in the software VnmrJ (Agilent 
Technologies, Santa Clara, CA, USA). A single exponential decay function was 
fitted to the magnitude images produced from MEMS data to acquire R2 maps. 
3.4.2 Measuring CBF and CBV - Arterial Spin Labeling (Papers II, III) 
ASL PWI was chosen rather than contrast enhanced PWI for several reasons. 
Firstly, ASL is non-invasive and does not require a venous injection of contrast 
agent. Secondly, in papers II-III, animals were examined repeatedly in proximity, 
which, due to the necessary wash-out time of contrast agents such as gadolinium, 
was possible only by the use of ASL(133). Finally, ASL allow the quantitative 
calculation of CBF (paper II-III) according to a well-established model originally 
described by Silva et al (134). 
Continuous ASL 
Continuous ASL PWI (paper II & III) was acquired by single-shot, gradient echo 
planar imaging in conjunction with continuous ASL by the application of off-
resonance radio frequency power to the ASL coil concurrently with a 1 Gauss/
cm gradient during TR. The position in the center of the applied slice package 
was located 2.4 cm downstream of the labelling plane. As well as tagged images, 
non-tagged control images were acquired with 25 repetitions per slice. Continuous 
ASL data was processed into CBF-maps (134)
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Turbo Dynamic ASL  
In paper III we used a technique known as T-DASL to measure CBVa according 
to a model previously described Meng et al (51) (Equation 5). In T-DASL, blood 
tagging and image acquisition are interleaved which enables a shorter acquisition 
times at the expense of a somewhat decreased labelling efficiency. The CBVa 
derived from T-DASL data was used to calculate values for OEF and CMRO2 
in paper III. OEF, which was the main focus of results presented in paper III, is 
proportional to R2’ and to CBVv. CBVv was derived from CBVa by the use of an 
arterial-venous partition fraction of 0.25(135). A summary description of T-DASL 
data acquisition is provided below and illustrated in Figure 8. 
The T-DASL acquisition began with a 10 s recovery period in order to establish 
magnetization equilibrium. An excitation pulse, as well as an echo planar imag-
ing readout module, were subsequently repeated 888 times (TR:67 ms) during the 
first 60, resulting in 888 images. Blood tagging was applied during the recovery 
times that occurred between excitation pulses and readout modules in 5 s periods 
which were repeated 5 times. After each 5 s period, tagging was stopped for 5 s in 
order to reestablish the steady state and to obtain non-tagged control images. After 
repeating this cycle 5 times (i.e at the conclusion of the 60 s scanning duration), the 
whole 60 s cycle was repeated but this time in the presence of vascular supression. 
Vascular suppression was achieved by utilizing of a pair of 1 ms gradients pulses 
which were applied parallel and antiparallel to the readout gradient direction. The 
acquired data was processed according to in-house Matlab (Mathworks, Nantucket) 




2αa· ξ - ∆M(b)⁄(M0(b)
In Equation 5, ∆M(0) and ∆M(b) define the difference between the first and last 
signal acquired during each 5 s T-DASL/readout cycle with (b) and without (0) 
vascular supression. M0(0) and M0(b) are the completely relaxed, initial signals 
acquired during each 5 s T-DASL/readout cycle with (b) and without (0) vascular 
supression. 2αa is the tagging efficiency achieved at position of the labelling plane. 
ξ describes the transverse relaxation rates R2* of blood and tissue, and is, due to 
the short TE used during acquisition, equal to 1. 
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Figure 8. MR signal collected from a region of hypoperfusion resulting from M2CAO 
(top panel) and from a healthy contra lateral control region (bottom panel). Panels show 
the 60 s cycle of T-DASL acquisition. Top panel: (a): The initial 10 s during which equi-
librium magnetization was allowed to recover. (b): 5 s interleaved excitation/ASL tagging 
pulse/readout. A clear drop in signal is visible as tagged blood reaches the imaging plane. 
The drop is less pronounced in the hypoperfused region than in the control region due to 
the decrease in CBF resulting from M2CAO (c): The 5 s period during which the steady 
state was reestablished and non-tagged control images were collected. (d): The difference 
in intensity between images collected with and without vascular supression. The signal 
difference consists of the vascular signal component. (e): The approximately 1 s inflow 
time during which tagged blood transits from the labeling plane to the imaging plane. 
Bottom panel: (f, g): M0(0) and M0(b) are the completely relaxed, initial signals acquired 
during each 5 s T-DASL/readout cycle with (b) and without (0) vascular supression. (h,i): 
∆M(0) and ∆M(b) and define the difference between the first and last signal acquired 
during each 5 s T-DASL/readout cycle with (b) and without (0) vascular supression. 
3.4.3 Imaging tissue oxygenation with MGE3D T2* (Paper III) 
Quantitative T2* imaging was used as the oxygen sensitive readout with which to 
establish R2′, and subsequently to calculate OEF and CMRO2, in the qBOLD regi-
men employed in paper III. T2* imaging was acquired with a MGE3D sequence 
with the following specifications: 12 evenly spaced TE ranging from 2.19 to 37.21 
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ms, a flip angle of 13 and TR: 70 ms. The acquired data underwent several steps 
of processing using in-house MATLAB scripts. The end product of the processing 
was R2* maps corrected for macroscopic field inhomogeneities. The R2* maps 
were subsequently matched with R2 maps, produced from MEMS imaging, and 
R2′ was calculated. 
3.4.4 Calculation of OEF and CMRO2 maps (Paper III) 
OEF and CMRO2 maps were calculated according to equations 2 and 3 using in-
house MATLAB scripts. Regularization to 1 was performed in such voxels where 
the calculated OEF equaled values > 1. Regularization was motivated by the fact 
that the extraction of oxygen in those voxels where OEF > 1 was deemed to be at 
its physiological maximum (100%). 
3.5 Positron emission tomography (Papers I, IV) 
3.5.1 [11C]PBR28 (Paper I) 
The [11C]PBR28 radiotracer was chosen due to improved signal-to-noise ratio 
and a decreased amount of non-specific binding when compared first generation 
TPSO-probes. Animals were examined on days 1, 4, 7, and 14 after undergoing 
90 min M2CAO. The mean injected radioactivity was 17.0 ± 1.0 MBq. Data was 
reconstructed into 25 time frames. A 3-dimensional penalized maximum likeli-
hood algorithm image reconstruction was performed using 20 iterations (MLEM; 
TeraTomoTM ; Mediso Ltd.). 
3.5.2 [18F]FMISO and [64Cu]CuATSM (Paper IV) 
 [18F]FMISO was used because it is the most investigated and most established PET 
radiotracer for the identification of cellular hypoxia resulting from AIS. Although 
the capacity of [18F]FMISO to identify hypoxia was not in question, the fact that 
the tracer requires a significant accumulation time before examinations can be 
performed underpins the interest in finding alternatives which could be applied 
in the hyperacute phase of AIS. One such alternative is [64Cu]CuATSM.  In the 
[18F]FMISO group, animals were administered [18F]FMISO within 30 min of the 
start of M2CAO. The average injected [18F]FMISO dose was 38.0 MBq. The 
radiotracer accumulated for 1 h before PET examinations were initiated. Images 
were collected every third minute for a total scan time of 30 min. In the [64Cu]
CuATSM group, radiotracer was administered 15 min after the start of M2CAO. 
The average injected dose was 20.4 MBq. Two 30 min PET examinations were 
performed. The initial examination was commenced right after the administration 
of [64Cu]CuATSM. Animals were moved to and examined in the MRI scanner at 
the end of the first PET examination. At the completion of the MRI scan, animals 
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were returned to the PET scanner where a second examination was begun. The 
image reconstruction was performed through standard 2D filtered back projection 
employing ramp filter. The reconstructed images had matrix sizes of 128 x 128 x 
95 and a pixel resolutions of 0.9 x 0.9 x 0.8 mm. 
3.6 Immunohistochemistry (Papers I, IV) 
Brains used for ICH analysis was fresh frozen immediately after being extracted from 
the animals. The tissue was subsequently sectioned at 12-14 µ. Immunofluorescent 
IHC was performed using standard protocols that included tyramidine signal ampli-
fication (TSA) (136). Please see original papers I & IV for detailed protocols. At 
the conclusion of ICH stainings, sections were scanned with 20x primary objec-
tive initial image capture on a Vslide slide scanning microscope (Metasystems, 
Altlußheim, Germany). Initial captures were stitched in the Vslide software 
(Metasystems) in order to assemble sectional images with microscopic resolu-
tion. In paper I, a data set using the antibodies NeuN and Cd68 was analyzed 
from micrographs collected through the use of a digital camera (Axiocam MRc5, 
Carl Zeiss AG) attached to a Zeiss microscope (Carl Zeiss AG, Jena, Germany). 
3.6.1 Profiling neuroinflammation 
 The antibodies used in the IHC analysis in paper I were selected on the basis that 
they should provide adequate specificity for those cell types exhibiting increased 
levels of TSPO during the inflammatory reaction that follows AIS. These cell types 
include activated microglia, the resident immune cells of the CNS, but also mono-
cytes/macrophages, as well as reactive astrocytes involved in glial scar formation 
and that are detectible with GFAP. Cd11b, was deemed a suitable biomarker consid-
ering it is not specific to microglia but is sensitive also to monocytes/macrophages. 
This allowed us to profile the full range of the neuroinflammatory reaction rather 
than microglia activation exclusively. The anti-TSPO antibody EPR5384 was used 
to profile the TSPO expression in these cell populations. 
3.6.2 Profiling cellular hypoxia 
In paper IV, we used an anti-pimonidazole antibody to correlate the in-vivo uptake of 
[18F]FMISO to ex-vivo IHC. Pimonidazole comes from the same Misonidazole fam-
ily of compounds as [18F]FMISO and is a well-established biomarker for hypoxia. 
We analyzed the distribution of pimonidazole in tissue and also the levels of pimo-
nidazole exhibited by neurons (NeuN) and astrocytes (GFAP). 
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4. RESULTS AND DISCUSSION 
The following section presents the most significant results contained in each of 
papers I-IV. Please see the original publications for a complete account of results, 
as well as for details on animal exclusions.  
4.1 Paper I  
4.1.1 Early Increase of [11C]PBR28 uptake in ischemic lesions 
In paper I we used [11C]PBR28 PET to examine longitudinally the emergence 
and progression of the neuroinflammatory response after 90 min M2CAO. PET 
results revealed significantly increased levels of TSPO within ischemic lesions on 
days 4, 7 and 14 after M2CAO, with the largest increase observed on day 4. No 
significant increase occurred in the contra lateral hemisphere at any time point. 
Please see Figure 9.A for an example of [11C]PBR28 PET uptakes on day 1 and 
4 after M2CAO. 
4.1.2 Immunohistochemistry reveals early monocyte/microglia 
activation 
PET examinations were complemented with immunofluorescent IHC analysis. 
Results are presented in Figure 10. On day 1, Cd11b positive+ cells of circular 
appearance were observed throughout lesions. Out of these only a small fraction 
exhibited TSPO upregulation. These cells were interpreted to be non-TSPO upregu-
lating cells such as neutrophils, which are known to arrive early after a cerebral 
insult(109, 113).  The analysis subsequently confirmed PET results by revealing a 
large increase in activated monocytes/microglia (Cd11b+/TSPO+) cells, as well as 
an increase in reactive astrocytes (GFAP+/TSPO+), in particular in the periphery 
of the lesion on day 4. From day 7, a significant increase of reactive astrocytosis 
in the form of glial scar formation was clearly visible around ischemic lesions. 
Please see Figure 9.B for confocal microcopy showing the co-localisation of 
Cd11b/TSPO and GFAP/TSPO.  
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Figure 9: A: Representative %SUV image of [11C]PBR28 uptake from day 1 and day 4 
overlaid on the average of all T2 MRI scans taken of the same animal across time points. 
B: Reconstructed confocal laser scanned micrographs at 4 days after M2CAO. I: GFAP+/
TSPO+ colocalisation in reactive astrocyte (closed arrows). Open arrowheads TSPO 
expression in cells negative for GFAP. j1–j3 Cd11b+/TSPO+ colocalisation in activated 
microglia/monocyte (closed arrows).
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Figure 10. Progression of GFAP+/TSPO+, Cd11b+/ TSPO+ and Cd11b+ (total) cell
load in ischemic regions of interest, from day 1 to day 14 after 90 min middle 
cerebral artery M2-segment occlusion (M2CAO).  
The number of Cd11b+/TSPO+ activated monocytes/microglia decreased after day 
4, but the total number of Cd11b+ cells continued to increase. On day 14, large and 
weakly Cd11+ cells exhibiting marginal TSPO intensity were the most common 
morphological type present in the lesion core. This was interpreted as an increase 
in the amoeboid, phagocytic phenotype of fully matured phagocytic cells at the 
expense of the immature/resting phenotypes of monocytes/microglia. However, 
cells exhibiting high TSPO intensities remained and were predominantly located 
in and around the newly formed glial scar. 
The neuroinflammatory reaction after AIS is a substantial component of the second-
ary injuries that occur in the days and weeks that follow the ischemic insult (108, 
137). The activation of microglia will entail a transformation from the ramified 
morphology, inherent to resting cells, to the large so-called amoeboid type which 
is hard to differentiate from those macrophages that enter the brain and which 
perform the debridement of necrotic tissue. 
Activation of microglia can be described as a double edge sword; beneficial effects 
such as the debridement of necrotic tissue and the promotion of large-scale tissue 
repair are counteracted by the production of proinflammatory mediators linked to a 
worsening of brain injury through the destruction of the neurovascular unit, as well 
as contributing to neuronal death by promoting apoptosis(137). The possibility to 
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better monitor and diagnose inflammatory progression is a long-standing objective 
in experimental as well as clinical AIS research. Experimental studies have now 
implicated microglia in the loss of BBB integrity(138), and demonstrated how 
up-regulating the M2 anti-inflammatory subtype of microglia at the expense of 
the proinflammatory M1 subtype benefits neurological outcomes(139). Thus far 
there are no effective therapeutic agents for the treatment of neuroinflammation 
following AIS, but in the future such agents may be developed. For this reasons 
an imaging probe capable of accurately examining tissue inflammation in the 
subacute phase of AIS is of high clinical relevance. [11C]PBR28 is well suited to 
this purpose. 
4.2 Paper II  
M2CAO produced a rapid accumulation of focal, cytotoxic edema that could be 
identified as restricted diffusion in ADC-maps as early as 10-30 min after the 
start of M2CAO (Figure 11.A). Results showed this rapid phase of increasingly 
restricted diffusion to occur predominantly during the initial 120-180 min fol-
lowing M2CAO, giving rise to ischemic core regions. There were similarities 
between the emergence of cytotoxic and vasogenic edema. The T2 signal in the 
ischemic core increased faster during the initial 120 min following M2CAO only 
to stabilize in a close to linear progression during subsequent time points (Figure 
11.B). Reperfusion produced a trend towards ADC normalization, while the rate 
of T2 signal elevation increased. 
4.2.1 Ischemic core expansion within DWI/PWI mismatch 
M2CAO produced a dramatic decrease in the CBF level of the ischemic core. 
Accordingly, the growth and progressive severity of the ischemic core was rapid 
in the initial phases. However, the continued expansion of irreversible damage was 
slow, and did not grow to encompass the entire region of DWI/PWI mismatch, 
even at 10 h of M2CAO. As in the ischemic core, CBF levels of the DWI/PWI 
mismatch, i.e. the penumbra ROI, were severely reduced by M2CAO. Results 
from the regional CBF analysis revealed, however, an incremental increase in 
the CBF levels both in the IC and the penumbra. We interpreted this as an effect 
increased collateral blood flow caused by the of the recruitment of LMAs. To 
confirm the sustained functionality of LMAs during M2CAO, the regional CBF 
of the penumbra and the ischemic core were correlated to the CBF levels present 
in the supply regions of the ACA and PCA which are not significantly affected 
by M2CAO. There was indeed a significantly stronger CBF correlation between 
the penumbra and the ACA than between the ACA and the ischemic core. The 
relative difference provides a strong indication of the beneficial effects of LMA 
recruitment on penumbra survival. Results are in agreement with previous reports 
describing how the rapid dilation of LMAs following MCAO causes a significant 
increase in the CBF of ischemic regions(18, 20). 
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The growth rate of the ischemic core in human AIS has been described as highly 
varying(65-67). The Ischemic core expands, as visualized with DWI MRI, in 
approximately 70% of patients and predominantly in cases where the acute phase 
DWI/PWI mismatch is large (32, 56, 57). Paper II showed a 11 percentage point 
increase of the ischemic lesion size when normalized against the size of the ini-
tial perfusion deficit caused by M2CAO. After 600 min M2CAO, the size of the 
ischemic lesion was at 27% of the initial size of perfusion deficit. This is compa-
rable to human patients where the DWI/PWI mismatch after 10 h of occlusion has 
been measured at 30%, although in those cases a further increase in the size of the 
ischemic lesion was documented in follow up examinations performed several days 
later(56). Please see Figure 12 for an example of how the DWI lesion expands at 
the expense of the DWI/PWI mismatch. 
Figure 11. The emergence and progression of ischemic injury. Apparent diffusion coefficient 
(ADC) and T2 signal ratios between regions of interest and control regions (y-axes), meas-
ured at subsequent time points (x-axes) during M2 occlusion (M2CAO)(A, B). Individual 
data points (diamonds); Equation trend lines (solid lines); confidence intervals (dotted lines). 
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Figure 12. Tissue injury progression during occlusion of the M2 segment of the MCA 
(M2CAO). Apparent diffusion coefficient (ADC) maps (mm2/s) (A) and cerebral blood 
flow (CBF) maps (ml/g/min) (B), of four sections from a single animal at 30, 90, 180 
and 600 min of M2CAO. At 30 min M2CAO, an ischemic core is already apparent. 
The lesions volume increases at subsequent time points. The expansion of the ischemic 
core occurs at the expense of the region of diffusion/perfusion mismatch. However, not 
even at 600 min does the ischemic lesion encompass the entirety of the perfusion deficit. 
4.3 Paper III
The aim of paper III was to employ oxygen-sensitive MRI to identify ischemic 
regions with increased OEF in order to delineate the ischemic penumbra. We 
used DWI to outline the ischemic core, and measured the volume of the ischemic 
core-OEF elevation (IC-OEF) mismatch. We also measured the volume of DWI/
PWI mismatch (IC-CBF) in the same animals. The volume of the of the IC-OEF 
mismatch was compared to, and found to be significantly smaller than the IC-CBF 
mismatch (Figure 13). The OEF of the IC-OEF mismatch was 90%, while the OEF 
of the healthy contra lateral control region was 40%. 
We further analyzed OEF and CMRO2 levels of tissue subjected to perfusion deficits 
severe enough to be consistent with tissue at high risk of infarction (12-22 ml/100 
g/min), but importantly not yet exhibiting the signs of restricted diffusion which 
would indicate an emergence of irreversible damage. The tissue was referred to 
as the penumbra ROI (PEN).  When compared to control regions, the PEN had 
significantly increased OEF levels and CMRO2 levels that, although significantly 
reduced, did not fall below the threshold for infarction at 65 μmol /100 g/min(132). 
Ischemic core regions also exhibited increased OEF during M2CAO. Reperfusion 
caused the normalization of OEF in both the ischemic core and the penumbra, 
emphasizing the potential of fast revasculatory treatment to achieve significant 
neurological recovery in AIS (Figure 14). 
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4.3.1 BOLD MRI may provide increased penumbra specificity  
The metabolic MRI protocol used in paper III was based on a qBOLD model devel-
oped by Yablonskiy et al. describing the relationship between R2' relaxation time, 
venous dHb fraction and CBVv in a network of randomly oriented cylinders(73). 
We combined R2' with the CBV-measuring capacity of T-DASL to calculate OEF 
maps over regions subjected to M2CAO. We found that the IC-OEF mismatch 
comprises a significantly smaller tissue volume than the IC-CBF mismatch in the 
same animals. These results were interpreted as an improvement of penumbra 
specificity based on several considerations. In human AIS patients, MCA infarct 
volumes resulting from large vessel occlusion commonly manifest at 4.5-14% of 
the hemispheric volume(125, 140). This matches the infarct volumes produced 
by M2CAO where mean infarct sizes are usually around 10% of the hemispheric 
volume. Results presented in paper II have shown us how the rate of irreversible 
damage expansion, although initially rapid, subsequently slows down and does not, 
even after 10 h M2CAO, encompass the entirety of the DWI/PWI mismatch region.
Figure 13. Volumetric Comparison of mismatch regions during M2CAO.
A: Examples of Regions of Interest from a single animal. Cerebral Blood Flow (CBF) 
and Oxygen Extraction Fraction (OEF) maps (left column). The Ischemic Core (red) was 
segmented in Apparent Diffusion Coefficient maps. The IC-CBF mismatch ROI (green) 
was defined as viable regions, with decreased CBF (top of the right column). The IC-OEF 
mismatch (orange) was defined as viable regions with an apparent OEF elevation (bottom 
of the right column). B: The volume of the IC-OEF mismatch was significantly smaller 
than the volume of the IC-CBF mismatch. 
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Figure 14. The oxygen extraction fraction (OEF) in ischemic regions during M2 occlusion 
(M2CAO) and after the restoration of blood flow (reperfusion). Top panel: Increased OEF 
occurred in the penumbra (A), and in the ischemic core (B) during M2CAO but normalized 
after reperfusion. The lower panel shows three axial slices from the same animal. Increased 
OEF is present in regions surrounding the infarct lesion (right column) during M2CAO. 
Reperfusion results in OEF normalization (middle column).  
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We conclude from this that a significant portion of the IC-CBF mismatch does not 
consist of tissue at an immediate risk of infarction. In view of these findings, a 
more spatially restricted outline of the ischemic penumbra would appear appropri-
ate, especially when taken into account that results from human AIS patients have 
shown the DWI lesion to make up just 30% of the of the PWI deficit volume when 
examined at 10 h after symptom onset(56). Furthermore, results presented in this 
study show how severely hypoperfused yet still viable tissue (CBF 12–22ml/100 
g/min) exhibits the metabolic adjustments, i.e increased OEF, necessary to sustain 
the CMRO2 levels needed for the continued viability of brain tissue(141). These 
results correspond well to previous results from DWI-PWI mismatch and peri-
infarct regions studied with 15O PET in human patients(42, 64, 142), as well as in 
experimental studies using animal stroke models of MCA occlusion(39, 143, 144). 
It should be mentioned also, that while OEF elevation in the ischemic penumbra 
has been previously described in studies employing gold standard 15O studies, in 
paper III, we observed increased OEF in regions suffering restricted diffusion. This 
documented increased in OEF in IC regions lends support to the view that fractions 
of the cells that make up regions with restricted diffusion actually remain meta-
bolically active as they accumulate cytotoxic edema. Does a significant fraction 
of the ADC lesion represent tissue that exists in the last phase of penumbra before 
undergoing destruction, and may this tissue be salvageable?  This is a worthwhile 
hypothesis for future studies. In conclusion, the development of metabolic imaging 
regimens akin to IC-OEF mismatch are motived by the potential gains of obtain-
ing measurements of tissue status in the acute and subacute phases of ischemic 
stroke as well as in CCH. 
4.3.2 Potential improvements 
The examination of oxygen metabolism with qBOLD is limited by the need to 
combine several MRI techniques. We used MEMS and MGE3D to derive R2ʹ, 
as well as continuous ASL and T-DASL to calculate the hemodynamic param-
eters of CBF and CBVv, respectively. Out of these methods T-DASL derived 
CBVv is the limiting factor in terms of spatial resolution and SNR. CBV levels 
were derived from the difference between the T-DASL signal in the presence and 
absence of vascular suppression. The relative uncertainty of CBV measurements 
thereby increases when the T-DASL signal is decreased. One would thus antici-
pate increased relative uncertainty in CBV in regions with low CBF. Put simply, 
the method would not work if there was no perfusion. Albeit the PEN ROIs had 
the lowest CBF and would be most susceptible to low SNR, the mean standard 
deviation within the penumbra ROIs was only approximately 0.025, which is a 
worst case estimate of the voxel wise uncertainty if there were no genuine CBV 
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variations within the penumbra region. In voxels with higher CBF, a lower CBV 
uncertainty is expected. On a group level, OEF was
consistently lower in control ROIs, while the OEF was elevated in regions with 
decreased CBF. Moreover, both OEF and the CBF moved toward normalization 
upon reperfusion. If random noise would dominate CBV measurements, this 
consistent pattern
would not be observed. In using T-DASL to calculate CBVv we were aware that 
SNR is inadequate to achieve the absolute OEF or CMRO2 values necessary to 
determine absolute penumbra thresholds. Accordingly, no such conclusions were 
presented in paper III. Despite the limitations of T-DASL, however, CBV values 
acquired in healthy control regions were in line those found in the literature(78, 
145).We conclude that the SNR of OEF is limited mainly by the SNR in CBVv, 
rather than the SNR in R2’. Future improvements of the methodology employed 
in paper III should focus on obtaining a more sensitive method to measure CBVv. 
4.4. Paper IV  
4.4.1 [18F]FMISO PET is sensitive to cellular hypoxia in AIS 
All but one of animal examined with [18F]FMISO PET exhibited apparent and 
localized uptake increase within the cortical part of the hemisphere subjected to 
M2CAO (Figure 15, top panel). The mean volume of regions exhibiting increased 
[18F]FMISO activity was 90 ± 70 mm2. This size is considerably larger than the 
typical size of ischemic lesions produced by the M2CAO model, which is usually 
in the range of 20-30 mm2. No apparent or localized increase in [64Cu]CuATSM 
uptake could be found in the M2CAO cortex of examined animals, not even when 
guided by ADC-maps outlining ischemic lesions with restricted diffusion. Our 
results thereby do not encourage the use of [64Cu]CuATSM in AIS research. [64Cu]
CuATSM is likely better suited for use in oncological imaging where the typical 
magnitude of hypoxia is more severe than in ischemic stroke. 
4.4.2 Hypoxia vulnerability of neurons and astrocytes 
IHC analysis revealed decreased amounts of GFAP+ astrocytes within hypoxic 
regions as defined by pimonidazole uptake (Figure 15, bottom panel, A) in a 
majority of the animals. No comparable decrease was seen in the population of 
NeuN+ neurons. The decrease in GFAP+ astrocytes was typically seen in an area 
smaller than the totality of the hypoxic region. The astrocytes and neurons located 
in hypoxic regions exhibited significantly higher levels of pimonidazole intensity 
than cells of corresponding cell types contained in contra lateral control regions. The 
loss of GFAP + astrocytes in hypoxic core regions has previously been correlated 
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to cell death(146, 147). Such regions are without question headed for infarction 
considering that neurons cannot survive without astrocytes in close proximity. To 
determine the respective levels of hypoxia of neurons and astrocytes, we measured 
the intensity ratios of pimonidazole in neurons and astrocytes by normalizing against 
non-hypoxic cells of corresponding cell types located in the control region. We 
found significantly higher pimonidazole intensities in neurons than in astrocytes. 
These results support the proposition that astrocytes are more sensitive to hypoxia 
than neurons, considering that astrocytes appear to undergo destruction prior to 
suffering the relative levels of hypoxia seen in neurons (144, 145). 
While the sensitivity of [18F]FMISO to hypoxic tissue is well documented, its 
penumbra specificity remains unknown. Results presented in paper IV demon-
strated a dearth of GFAP+ astrocytes in hypoxic core areas while astrocytes were 
still present in the periphery of the hypoxic region. We conclude from these results 
that although [18F]FMISO uptake does identify viable, hypoxic tissue, it may also 
be present in irreversibly damaged regions. [18F]FMISO should thereby be used in 
conjunction with an imaging modality capable of identifying the ischemic core, 
such as CT or DWI MRI. Such examinations will be possible using hybrid systems 
such as MRI/PET and CT/PET(148). 
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Figure 15. Top panel: [18F]FMISO examination of a single animal during M2CAO; axial 
(left image), coronal (middle) and sagittal (right) projections. A focal area of increased [18F]
FMISO uptake is apparent in the cortex subjected to M2CAO. Lower panel: A1: M2CAO 
cortex delineated by white line. Pimonidazole (blue, A2), GFAP+ astrocytes (green, A3) 
and NeuN+ neurons (red, A4). There is a loss of astrocytes in the core of the hypoxic 
region as seen in H1. P-H: M2CAO cortex without clear pimonidazole uptake. H2: hypoxic 
region inside the striatum. B1: The loss of astrocytes is apparent in the core of a hypoxic 
region (a). Although still present, there is a diminished presence of astrocytes, as well as 
an increased concentration of pimonidazole+ astrocytes and neurons in the border area of 
the hypoxic region (b) when compared to tissue outside of the hypoxic region (c). B2-B5 
(magnification of the white square in B1): Hypoxic astrocytes (arrowheads) and neurons 
(arrows). Scale bars: A1: 500 μm, B1: 50 μm, B2-B5: 10 μm. 
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5. CONCLUSIONS 
(I) [11C]PBR28 is a suitable radiotracer with which to monitor the progres-
sion of neuroinflammation during AIS as modelled by M2CAO. 
(II) In AIS as modelled by M2CAO, there is a rapid emergence of an 
ischemic lesion. However, the subsequent spread of infarction at the 
expense of the surrounding hypoperfused tissue is slow, and continues 
for many hours after arterial occlusion. Not all tissue contained in the 
DWI/PWI mismatch is at risk of infarction.  
(III) When combined with DWI, oxygen metabolism MRI provides increased 
penumbra specificity when compared to the DWI/PWI mismatch. 
Oxygen metabolism MRI seems well suited for applications in sub-
acute and slow-progressing AIS and CCH. 
(IV)  Although limited by its substantial accumulation time, if combined 
with a DWI or CT, [18F]FMISO PET may be a valuable instrument for 
the identification of tissue-at-risk in subacute ischemic stroke and in 
cases of CCH. Astrocytes are likely to be more sensitive to hypoxia 
than neurons in the hyperacute phase of AIS. [64Cu]CuATSM does not 
appear suited for the identification of tissue-at-risk in AIS. 
45
6. FUTURE PERSPECTIVES 
Recent decades have seen the emergence of various imaging-methods attempting 
to provide reliable identification of the ischemic penumbra through hemodynamic 
and metabolic read-outs. The ambition has been to locate an adequate intersec-
tion between accuracy and clinical availability; however, attempts to improve 
penumbra specificity have come at the expense of translational potential.  In order 
to overcome this junction, the question should be asked as to what is required of 
imaging techniques in order to make them suitable for clinical application. With 
irreversible brain injury in most AIS cases progressing rapidly during severe 
ischemia, the necessity of short examination times is not in question. Revasculatory 
treatment must not be delayed by unnecessary imaging. A reasonably accurate 
estimate of the volume of infarct is needed, motivated by the fact that this is the 
relevant parameter when assessing the risk of a hemorrhage or other complications 
resulting from the treatment. In order to motivate treatment in the first place, a 
measurement of potentially salvageable tissue must also be obtained. Since 2015, 
the beneficial effects of mechanical thrombectomy when supported by diagnostic 
imaging has been shown in several randomized trials(4). Imaging protocols such 
as CT perfusion and MRI DWI/PWI mismatch are capable of identifying patients 
suitable for treatment on the basis of limited infarctions and large regions exhib-
iting hypoperfusion(149). The resurrection of blood flow to salvageable tissue 
may in best-case scenarios restore full health to AIS patients, providing that the 
therapeutic intervention occurs early enough, as time is brain.  Does that mean that 
the time from the last-known-well is in itself adequate for the triage of individual 
patients? The answer is no, and for several reasons; for one, a substantial propor-
tion of AIS cases occur during sleep, rendering the time of onset highly uncertain. 
Even in patients who are awake when ictus occurs the onset of symptoms may 
not accurately correspond to the time of vascular occlusion. In addition, the rate 
of infarct progression is heterogeneous between patients. While the time is brain 
paradigm is suitable during the initial hours after ictus, a substantial number of 
patients will not receive recanalizing treatment because they arrive at hospital 
after the time-window indicating acute intervention, or because they have an 
uncertain time of onset. There are now an increasing number of clinical observa-
tions proposing the potential of penumbra viability beyond the short, hyperacute 
phase of AIS. The DAWN trial showed the benefits of delayed thrombectomy in 
patients with limited ischemic lesions in conjunction with a clinical presentation 
indicating the presence of functionally impaired, i.e. penumbral, tissue as long as 
24 h after ictus(7). The DEFUSE 3 trial presented similar results but up to 16 h 
after ictus in patients with large hypoperfused regions as well as limited detect-
able infarcts using CT or MRI(8). The prospect of prolonged penumbra viability 
encourages the development and implementation of imaging techniques capable 
of directly assessing tissue status rather than indirect measurements such as PWI 
when handling the substantial proportion (30%) of large vessel AIS patients who 
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suffer slow-progressing infarcts, and who arrive at hospital beyond the initial 6 
h of AIS(150, 151). The uncertainty inherent to PWI will be increased in these 
patients, considering that survival time of ischemic tissue-at-risk is determined 
both by the duration and the severity of a perfusion deficit. In addition, patients 
presenting with arterial neck dissections and incomplete circle of Willis sometimes 
exhibit symptoms consistent with CCH, as do patients with advanced chronic 
atherosclerotic lesions either proximal or distal to the circle of Willis. In these 
patients it is often challenging to determine whether the symptoms are due to 
hypoperfusion or not, and if the potential benefits of revasculatory treatment out-
weigh the associated risks. Clinical decision-making would thereby be facilitated 
by diagnostic imaging capable of increased penumbra specificity. In this context, 
metabolic MRI, as well as hypoxia PET are viable candidates to improve stroke 
health care by enhancing penumbra specificity in the subacute phase and in CCH 
where slightly longer examination times are not as detrimental to the individual 
patient. Although it is the case that several of the imaging techniques used in 
experimental research have little immediate potential for large-scale clinical trans-
lation, they remain valuable for the validation and improvement of more readily 
available methods. In fact, MRI as well as PET continue to contribute substan-
tially to the understanding of pathophysiological processes both in the context of 
acute ischemia and in the chronic phase when secondary injury mechanism such 
as neuroinflammation impact on clinical outcome. The translational potential of 
experimental research consistently improves with technical advancements such as 
the emergence of hybrid systems capable of simultaneous PET/MRI or PET/CT 
examinations. Technological advances include the implementation of novel radi-
otracers designed to better visualize ischemic injury and the neuroinflammatory 
response following AIS(152, 153).  The continuing focus on methods for in-vivo 
imaging of AIS-associated disease processes in experimental research is warranted 
by the potential to improve the diagnostic regimes currently used in clinical set-
tings, and by the need to ensure that proposed neuroprotective and neurorestorative 
treatment strategies can be accurately evaluated. This is especially relevant in the 
field of neuroinflammation, where pharmacological agents capable of modulat-
ing the inflammatory response may in the future reduce the neurological deficits 
suffered by stroke patients.
In conclusion, Protocols akin to the metabolic MRI described in this thesis should 
be improved by shorter examination times and increased SNR. As with PET hypoxia 
imaging, it is crucial that their capability to identify penumbra is validated against 
150 PET in human stroke patients. If successful, metabolic MRI as well as PET 
hypoxia imaging may provide increased diagnostic power especially pertinent 
to the subacute phase of stroke as well as in CCH where determining tissue sta-
tus may be more appropriate than counting the hours since the last-known-well. 
Future studies on AIS imaging should focus also on clarifying whether fractions 
of regions exhibiting restricted diffusion, currently considered to be irreversibly 
damaged, may in fact be salvageable in the very early phase of AIS.
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